Jeffrey V Ravetch (Jeffrey Ravetch)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 35

Top Topics

Monoclonal Antibody

Immune Response

Natural Killer Cells

Top Venues

Proceedings of the National Academy of Sciences of the United States of America

Cancer immunology research

Research square

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

David A Knorr, Lucas Blanchard, Rom S Leidner, Shawn M Jensen, Ryan Meng, Andrew T Jones, Carmen Ballesteros-Merino, Richard B Bell, Maria Baez, Alessandra Marino, David Sprott, Carlo B Bifulco, Brian D Piening, Rony Dahan, Juan C Osorio, Bernard A Fox, Jeffrey V Ravetch
FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment. Cancer immunology research 12 (3) (2024)
David A Knorr, Lucas Blanchard, Rom S Leidner, Shawn M Jensen, Ryan Meng, Andrew T Jones, Carmen Ballesteros-Merino, Richard B Bell, Maria Baez, Alessandra Marino, David Sprott, Carlo B Bifulco, Brian D Piening, Rony Dahan, Juan C Osorio, Bernard A Fox, Jeffrey V Ravetch
FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment. Cancer immunology research 12 (3) (2024)
David A Knorr, Lucas Blanchard, Rom S Leidner, Shawn M Jensen, Ryan Meng, Andrew T Jones, Carmen Ballesteros-Merino, Richard B Bell, Maria Baez, Alessandra Marino, David Sprott, Carlo B Bifulco, Brian D Piening, Rony Dahan, Juan C Osorio, Bernard A Fox, Jeffrey V Ravetch
FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment. Cancer immunology research 12 (3) (2024)
Juan C Osorio, David Knorr, Polina Weitzenfeld, Ning Yao, Maria Baez, Meghan DiLillo, Jahan A Rahman, Jacqueline F Bromberg, Michael A Postow, Charlotte E Ariyan, Mark E Robson, Jeffrey V Ravetch
Intratumoral Fc-optimized agonistic CD40 antibody induces tumor rejection and systemic antitumor immunity in patients with metastatic cancer. Research square (2024)
Juan C Osorio, David A Knorr, Polina Weitzenfeld, Ning Yao, Maria Baez, Meghan DiLillo, Jahan A Rahman, Jacqueline F Bromberg, Michael A Postow, Charlotte E Ariyan, Mark E Robson, Jeffrey V Ravetch
Intratumoral Fc-optimized agonistic CD40 antibody induces tumor rejection and systemic antitumor immunity in patients with metastatic cancer. Research square (2024)
Julia E Edgar, Stephanie Trezise, Robert M Anthony, Florian Krammer, Peter Palese, Jeffrey V Ravetch, Stylianos Bournazos
Antibodies elicited in humans upon chimeric hemagglutinin-based influenza virus vaccination confer FcγR-dependent protection in vivo. Proceedings of the National Academy of Sciences of the United States of America 120 (44) (2023)
David A Knorr, Lucas Blanchard, Rom S Leidner, Shawn M Jensen, Ryan Meng, Andrew T Jones, Carmen Ballesteros-Merino, Richard B Bell, Maria Baez, Alessandra Marino, David Sprott, Carlo B Bifulco, Brian D Piening, Rony Dahan, Juan C Osorio, Bernard A Fox, Jeffrey V Ravetch
FcγRIIB is an immune checkpoint limiting the activity of Treg-targeting antibodies in the tumor microenvironment. Cancer immunology research (2023)
Aaron Gupta, Kevin S Kao, Rachel Yamin, Deena A Oren, Yehuda Goldgur, Jonathan Du, Pete Lollar, Eric John Sundberg, Jeffrey V Ravetch
Mechanism of glycoform specificity and in vivo protection by an anti-afucosylated IgG nanobody. Nature communications 14 (1) (2023)
Aaron Gupta, Kevin S Kao, Rachel Yamin, Deena A Oren, Yehuda Goldgur, Jonathan Du, Pete Lollar, Eric John Sundberg, Jeffrey V Ravetch
Mechanism of glycoform specificity and in vivo protection by an anti-afucosylated IgG nanobody. Nature communications 14 (1) (2023)
Jeffrey L Wong, Patrick Smith, Juan Angulo-Lozano, Daniel Ranti, Bernard H Bochner, John P Sfakianos, Amir Horowitz, Jeffrey V Ravetch, David A Knorr
IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer. Proceedings of the National Academy of Sciences of the United States of America 120 (35) (2023)
David A Knorr, Lucas Blanchard, Rom S Leidner, Shawn M Jensen, Ryan Meng, Andrew T Jones, Carmen Ballesteros-Merino, Richard B Bell, Maria Baez, Alessandra Marino, David Sprott, Carlo B Bifulco, Brian D Piening, Rony Dahan, Juan C Osorio, Bernard A Fox, Jeffrey V Ravetch
FcγRIIB is an immune checkpoint limiting the activity of Treg-targeting antibodies in the tumor microenvironment. Cancer immunology research (2023)
Rachel Yamin, Kevin S Kao, Margaret R MacDonald, Tineke Cantaert, Charles M Rice, Jeffrey V Ravetch, Stylianos Bournazos
Human FcγRIIIa activation on splenic macrophages drives dengue pathogenesis in mice. Nature microbiology (2023)
Katherine Knorr, Jahan Rahman, Caroline Erickson, Eric Wang, Mara Monetti, Zhuoning Li, Juliana Ortiz-Pacheco, Andrew Jones, Sydney X Lu, Robert F Stanley, Maria Baez, Nina Fox, Cynthia Castro, Alessandra E Marino, Caroline Jiang, Alexander V Penson, Simon J Hogg, Xiaoli Mi, Hideaki Nakajima, Hiroyoshi Kunimoto, Koutarou Nishimura, Daichi Inoue, Benjamin D Greenbaum, David Knorr, Jeffrey V Ravetch, Omar Abdel-Wahab
Systematic evaluation of AML-associated antigens identifies anti-U5 SNRNP200 therapeutic antibodies for the treatment of acute myeloid leukemia. Nature cancer (2023)
Aaron Gupta, Kevin S Kao, Rachel Yamin, Deena A Oren, Yehuda Goldgur, Jonathan Du, Pete Lollar, Eric John Sundberg, Jeffrey V Ravetch
Mechanism of glycoform specificity and in vivo protection by an anti-afucosylated IgG nanobody. Nature communications 14 (1) (2023)
Aaron Gupta, Kevin Kao, Rachel Yamin, Deena A Oren, Yehuda Goldgur, Jonathan J Du, Pete Lollar, Eric John Sundberg, Jeffrey V Ravetch
Mechanism of glycoform specificity and protection against antibody dependent enhancement by an anti-afucosylated IgG nanobody. bioRxiv : the preprint server for biology (2023)
David A Knorr, Lucas Blanchard, Rom S Leidner, Shawn M Jensen, Ryan Meng, Andrew T Jones, Carmen Ballesteros-Merino, Richard B Bell, Maria Baez, Alessandra Marino, David Sprott, Carlo B Bifulco, Brian D Piening, Rony Dahan, Juan C Osorio, Bernard A Fox, Jeffrey V Ravetch
FcγRIIB is an immune checkpoint limiting the activity of Treg-targeting antibodies in the tumor microenvironment. Cancer immunology research (2023)
Aaron Gupta, Patrick Smith, Stylianos Bournazos, Jeffrey V Ravetch
A novel mouse strain optimized for chronic human antibody administration. Proceedings of the National Academy of Sciences of the United States of America 119 (10) (2022)
Ramin Sedaghat Herati, David A Knorr, Laura A Vella, Luisa Victoria Silva, Lakshmi Chilukuri, Sokratis A Apostolidis, Alexander C Huang, Alexander Muselman, Sasikanth Manne, Oliva Kuthuru, Ryan P Staupe, Sharon A Adamski, Senthil Kannan, Raj K Kurupati, Hildegund C J Ertl, Jeffrey L Wong, Stylianos Bournazos, Suzanne McGettigan, Lynn M Schuchter, Ritesh R Kotecha, Samuel A Funt, Martin H Voss, Robert J Motzer, Chung-Han Lee, Dean F Bajorin, Tara C Mitchell, Jeffrey V Ravetch, E John Wherry
PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine. Nature immunology 23 (8) (2022)
Kevin S Kao, Aaron Gupta, Guanghui Zong, Chao Li, Isabell Kerschbaumer, Sara Borghi, Jacqueline M Achkar, Stylianos Bournazos, Lai-Xi Wang, Jeffrey V Ravetch
Synthetic nanobodies as tools to distinguish IgG Fc glycoforms. Proceedings of the National Academy of Sciences of the United States of America 119 (48) (2022)
Christopher S Garris, Jeffrey L Wong, Jeffrey V Ravetch, David A Knorr
Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer. Science translational medicine 13 (594) (2021)
Stylianos Bournazos, Hoa Thi My Vo, Veasna Duong, Heidi Auerswald, Sowath Ly, Anavaj Sakuntabhai, Philippe Dussart, Tineke Cantaert, Jeffrey V Ravetch
Antibody fucosylation predicts disease severity in secondary dengue infection. Science (New York, N.Y.) 372 (6546) (2021)
Jeffrey V Ravetch, Rachel Yamin, Andrew Jones, Hans-Heinrich Hoffmann, Kevin Kao, Rebecca Francis, Timothy P Sheahan, Ralph S Baric, Charles M Rice, Stylianos Bournazos
Fc-engineered antibody therapeutics with improved efficacy against COVID-19. Research square (2021)
Rachel Yamin, Andrew T Jones, Hans-Heinrich Hoffmann, Alexandra Schäfer, Kevin S Kao, Rebecca L Francis, Timothy P Sheahan, Ralph S Baric, Charles M Rice, Jeffrey V Ravetch, Stylianos Bournazos
Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy. Nature 599 (7885) (2021)
Itziar Ibarlucea-Benitez, Polina Weitzenfeld, Patrick Smith, Jeffrey V Ravetch
Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity. Proceedings of the National Academy of Sciences of the United States of America 118 (26) (2021)
Stylianos Bournazos, Davide Corti, Herbert W Virgin, Jeffrey V Ravetch
Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection. Nature 588 (7838) (2020)
Stylianos Bournazos, Aaron Gupta, Jeffrey V Ravetch
The role of IgG Fc receptors in antibody-dependent enhancement. Nature reviews. Immunology 20 (10) (2020)
Sara Borghi, Stylianos Bournazos, Natalie K Thulin, Chao Li, Anna Gajewski, Robert W Sherwood, Sheng Zhang, Eva Harris, Prasanna Jagannathan, Lai-Xi Wang, Jeffrey V Ravetch, Taia T Wang
FcRn, but not FcγRs, drives maternal-fetal transplacental transport of human IgG antibodies. Proceedings of the National Academy of Sciences of the United States of America 117 (23) (2020)
Silke Eisinger, Dhifaf Sarhan, Vanessa F Boura, Itziar Ibarlucea-Benitez, Sofia Tyystjärvi, Ganna Oliynyk, Marie Arsenian Henriksson, David Lane, Stina Linnea Wickström, Rolf Kiessling, Tommaso Virgilio, Santiago Fernandez Gonzalez, Dagmara Kaczynska, Shigeaki Kanatani, Evangelia Daskalaki, Craig E Wheelock, Saikiran K Sedimbi, Benedict J Chambers, Jeffrey V Ravetch, Mikael C I Karlsson
Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells. Proceedings of the National Academy of Sciences of the United States of America 117 (50) (2020)
Koen K A Van Rompay, Lark L Coffey, Tania Kapoor, Anna Gazumyan, Rebekah I Keesler, Andrea Jurado, Avery A Peace, Marianna Agudelo, Jennifer Watanabe, Jodie Usachenko, Anil Singapuri, Ramya Immareddy, Amir Ardeshir, Jackson B Stuart, Stylianos Bournazos, Jeffrey V Ravetch, Paul J Balderes, Ivo C Lorenz, Shannon R Esswein, Jennifer R Keeffe, Pamela J Bjorkman, Qiao Wang, Charles M Rice, Margaret R MacDonald, Michel C Nussenzweig, Davide F Robbiani
A combination of two human monoclonal antibodies limits fetal damage by Zika virus in macaques. Proceedings of the National Academy of Sciences of the United States of America 117 (14) (2020)
Anum Azam Glasgow, Jeff E Glasgow, Daniel Limonta, Paige Solomon, Irene Lui, Sunny Zhang, Matthew A Nix, Nicholas J Rettko, Beth Shoshanna Zha, Rachel Yamin, Kevin Kao, Oren S Rosenberg, Jeffrey V Ravetch, Arun P Wiita, Kevin K Leung, Shion An Lim, Xin X Zhou, Tom C Hobman, Tanja Kortemme, James A Wells
Engineered ACE2 receptor traps potently neutralize SARS-CoV-2. Proceedings of the National Academy of Sciences of the United States of America 117 (45) (2020)
Stylianos Bournazos, David J DiLillo, Arthur J Goff, Pamela J Glass, Jeffrey V Ravetch
Differential requirements for FcγR engagement by protective antibodies against Ebola virus. Proceedings of the National Academy of Sciences of the United States of America 116 (40) (2019)
John P Giddens, Joseph V Lomino, David J DiLillo, Jeffrey V Ravetch, Lai-Xi Wang
Site-selective chemoenzymatic glycoengineering of Fab and Fc glycans of a therapeutic antibody. Proceedings of the National Academy of Sciences of the United States of America 115 (47) (2018)
David A Knorr, Rony Dahan, Jeffrey V Ravetch
Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity. Proceedings of the National Academy of Sciences of the United States of America 115 (43) (2018)
Meili Zhang, Bernard Wen, Olga M Anton, Zhengsheng Yao, Sigrid Dubois, Wei Ju, Noriko Sato, David J DiLillo, Richard N Bamford, Jeffrey V Ravetch, Thomas A Waldmann
IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages. Proceedings of the National Academy of Sciences of the United States of America 115 (46) (2018)
Jad Maamary, Taia T Wang, Gene S Tan, Peter Palese, Jeffrey V Ravetch
Increasing the breadth and potency of response to the seasonal influenza virus vaccine by immune complex immunization. Proceedings of the National Academy of Sciences of the United States of America 114 (38) (2017)